Representational difference analysis (RDA) of human breast cancer was used to discover a novel amplicon located at chromosomal region 8q24.3. We examined a series of breast cancer samples harboring amplification of this region and determined that KCNK9 is the sole overexpressed gene within the amplification epicenter. KCNK9 encodes a potassium channel that is amplified from 3-fold to 10-fold in 10% of breast tumors and overexpressed from 5-fold to over 100-fold in 44% of breast tumors. Overexpression of KCNK9 in cell lines promotes tumor formation and confers resistance to both hypoxia and serum deprivation, suggesting that its amplification and overexpression plays a physiologically important role in human breast cancer.
Introduction
four DNA probes that all originated from a 550 kb region of a novel breast cancer amplicon. High-resolution mapping led to the identification of a single overexpressed gene, KCNK9, that Amplification of oncogenes such as HER2 and CCND1 is one of the key genetic mechanisms underlying the development of was shown in functional studies to convey properties highly consistent with a role in tumor formation. human breast cancer. The size of the genomic region surrounding oncogenes that is amplified in tumors can vary considerably, from 700 kb to 4.5 Mb for CCND1 and from 350 kb to Results over 1 Mb for NMYC (Tanigami et al., 1992; Hiemstra et al., 1994) . Genes that are coamplified along with the "driver" gene
We applied RDA to a series of breast tumor samples and tested the resultant cloned sequences for their ability to detect geno-underlying selective amplification are often overexpressed (Wimmer et al., 1999; Pollack et al., 2002) . Consequently, over-mic amplification by DNA hybridization. From one particular cancer sample, we isolated six RDA-derived sequences (RDA expression of an amplified gene in and of itself is not convincing evidence for a role in tumor formation. More compelling genetic probes) that detected amplification, two of which were mapped by analysis of radiation-hybrid panels to the HER2 locus, and evidence for a gene's candidacy as a "driver" gene comes from high-resolution mapping of amplicon boundaries, which to date the other four of which were mapped to chromosomal region 8q24.3, approximately 10 Mb telomeric to the MYC oncogene. remains labor intensive and has been carried out in only a few cases of reported candidate breast cancer-amplified onco-An initial survey of breast tumors by DNA hybridization showed that the 8q24.3 RDA probes detected amplification (4-fold to genes, including ZNF217, CYP24, and PPM1D Albertson et al., 2000; Li et al., 2002) . 10-fold) in 4 out of 70 primary breast tumors. Two of these four tumors harboring amplification also showed 3-fold amplification In this report, RDA (Lisitsyn et al., 1995) was used to isolate
S I G N I F I C A N C E
Many of the genetic alterations that drive the development and progression of sporadic breast cancer remain poorly characterized. Whole-genome approaches that can pinpoint relatively small genomic aberrations at high resolution allow identification of potentially causative cancer genes. Here, RDA was used to find a 550 kb amplicon containing only one overexpressed gene, KCNK9. Functional analysis of KCNK9 has established its ability to act as a dominant oncogene, making KCNK9 a potential target in treatment of tumors presenting amplification and overexpression of KCNK9. Additionally, our finding that KCNK9 overexpression confers resistance to hypoxia, together with its reported role in mediating other oxygen-sensitive physiological responses, opens up a potential new line of investigation into the development of hypoxia tolerance in tumor cells.
of MYC, whereas the other two tumors were not amplified for MYC, indicating that amplification of this region can occur independently. We performed a more extensive survey of primary invasive breast cancers with quantitative PCR and determined that 24 out of 247 breast tumors (approximately 10%) were amplified for this locus (3-fold to 10-fold, data not shown).
As a first step to find the gene underlying the selective amplification of this region, the four 8q24.3 RDA probes and nearby sequence-tagged sites (STSs) were used to isolate human genomic DNA clones. These clones were sequenced and the resultant genomic sequence was used to construct a map of the amplified locus. To identify the amplification epicenter, the genomic amplification status of STSs distributed across this locus was determined in a set of five amplified tumors and cancer cell lines. Two samples displayed equal copy number increase (3-fold to 5-fold) throughout the 1.3 Mb region analyzed, suggesting that other genes outside of this region may provide selective pressure for increased genomic copy number in these tumors (data not shown). However, we identified a clearly delineated 550 kb amplicon in the primary tumor from which the RDA-derived sequences were obtained and an overlapping 700 kb amplicon in the breast cancer cell line ZR-75-30 ( Figure 1 ). This 550 kb amplified region was also present in the broader amplicon of an additional primary tumor ( Figure 1 ). outside of the region (Figure 1 ). We failed to detect by Northern Although the data shown is from single DNA TaqMan assays (each with hybridization a smaller mRNA than the normal sized 4 kb mestriplicate measurements with coefficient of variation [CV] of less than 3%), each assay was performed 2 to 3 times with an average CV of 9% and sage in the highly amplified breast cancer cell line ZR-75-30, range from less than 1% to 17%. However, the variability seen in DNA copy ruling out the possibility that a truncated version of the gene number from one probe to the next probe along the genome is sometimes was activated in the tumors (data not shown). Furthermore, T1 greater than 17% and does not always appear to reflect true changes in was not overexpressed in a number of other tumor samples DNA copy number. Based on unpublished results, this variability is due in part to susceptibility of individual TaqMan probe efficiencies to currently (data not shown), strongly suggesting that it was not the gene unknown differences in the composition of the tumor sample DNA. Based on providing the selective pressure for genomic amplification. this variability, several adjacent TaqMan probes were designed to delineate The other gene was identified with the gene prediction proamplicon boundaries with greater confidence.
gram GeneMachine (Makalowska et al., 2001 ) based on sequence homology to the two-pore potassium channel gene KCNK3. A full-length cDNA for this gene, which we termed KCNB, was cloned and we determined that its entire sequence as exhibiting overexpression if the relative value was greater is located within the 550 kb amplicon (Figure 1 ). Subsequently, than 5-fold. Using Fisher's exact test, there was a highly signifiother groups studying two-pore potassium channels cloned this cant correlation between DNA copy number and RNA overexsame gene they termed TASK-3 (Kim et al., 2000; Rajan et al., pression (p ϭ 0.0001). Thus, like the HER2 oncogene (Pauletti 2000; Chapman et al., 2000) . Hereafter we adopt the officially et al., 1996) , the majority of cases in which KCNK9 is overexsanctioned gene symbol KCNK9 (http://www.gene.ucl.ac.uk/). pressed in breast and lung cancers correlates with amplification KCNK9 was overexpressed at least 5-fold and up to over 100or more modest gain of genomic DNA. fold in 28 out of 64 breast cancers (44%), including all breast Antipeptide antibodies directed against the KCNK9 gene tumors that were amplified for this region as well as tumors in product were employed to determine the frequency of overexwhich the genomic DNA was not highly amplified (Table 1 ). In pression in breast cancers by immunohistochemical analysis of addition to breast cancers, KCNK9 was overexpressed in 35% normal and tumor tissue microarrays (Kononen et al., 1998) . of lung cancers (Table 1) .
Twenty-nine out of 71 breast tumor samples surveyed showed To test whether there was a correlation of amplification and/ KCNK9 protein overexpression, whereas none of the 14 normal or low-level DNA copy number increase with increased gene breast samples showed overexpression ( Figure 2) . These numexpression, we classified tumors as harboring DNA copy numbers are in close agreement to the frequency of overexpression determined by quantitative reverse transcriptase (RT)-directed ber increase if the relative value was greater than 1.5-fold, and KCNK9 overexpression also strongly enhanced tumorige- Graeber et al., 1996) . Furthermore, in this model, TP53-containing cells by several weeks (Figure 3B ). In cell cul- jected to hypoxia ( Figure 4B ). KCNK9 overexpression allowed 
Discussion
Relative DNA copy number and relative RNA expression levels were determined by real-time quantitative PCR assays, and the data shown are the mean values of duplicate or triplicate assays. Relative values above 100
The functional studies presented here, taken together with the are shown as Ͼ100. The coefficient of variation for relative DNA copy numlocation of KCNK9 within an amplification epicenter, strongly ber measurements was Յ15%, and that of relative RNA expression levels suggest that amplification and overexpression of KCNK9 prowas Յ27%.
vides a selective advantage to breast cancer cells. Although it
Lung tumor samples are subdivided as indicated: a not classified, b small-cell lung cancer, c carcinoid, d squamous cell carcinoma, e adenocarcinoma, has been known for years that potassium or other ion channels and f bronchioepithelial,.
can be activated by mitogens or oncogenes (Thomas and Brugge, 1997) , our results are the first indication that genetic alteration of an ion channel gene can play a direct role in cancer.
There is a high incidence of copy number gains that affect the 8q chromosome arm in multiple cancers, including breast PCR measurements (44%). In contrast, the human protein that carcinomas where 8q gains occur in 40% or more of all tumors has the closest sequence match to KCNK9, KCNK3, was not (Struski et al., 2002) . The recurrent selection for this large region preferentially expressed in tumor tissue as judged by immunoof the genome implies that multiple genes in addition to MYC histochemistry, nor was the KCNK3 gene amplified or overexare being selected as "driver" genes to promote tumorigenesis. pressed in breast or lung cancers, based on quantitative PCR The data presented here identifies KCNK9 as a new protooncoanalysis (data not shown).
gene that may provide selective pressure for copy number in-We utilized immunohistochemistry to ascertain whether creases at chromosome 8q, and in particular 8q24.3. there was a correlation of overexpression of KCNK9 with either
Our studies indicate that one potential mechanism by which HER2 overexpression or expression of estrogen receptors. In KCNK9 overexpression may contribute to tumorigenesis is by a set of 50 tumors, we did not detect a statistically significant promoting cancer cell survival in the poorly oxygenated areas correlation of KCNK9 overexpression with either estrogen reof solid tumors. In view of a recent report implicating KCNK9 ceptor expression or HER2 overexpression (p ϭ 0.1781 and as a key mediator of physiological effects of hypoxia in a human 0.3978, respectively). Thus, there does not appear to be a spelung cancer cell line (Hartness et al., 2001) , it is tempting to cific requirement for KCNK9 overexpression to collaborate with speculate that the protection from hypoxia we observed is rethese pathways.
lated to an ability of the KCNK9 channel to respond to oxygen As the next step to ascertain whether KCNK9 is a target levels. The ability to suppress tumorigenicity by interfering with oncogene whose amplification and overexpression could provide a selective advantage to tumor cells, KCNK9 was deliberately the ability to respond to lowered oxygen levels has previously overexpressed in different cell lines, and phenotypes associated been demonstrated (Kung et al., 2000) . It will be important to with tumorigenesis were assessed. KCNK9 overexpression did determine whether inhibiting KCNK9 function will disrupt renot transform NIH-3T3 fibroblasts or NMuMG, a cell line derived sponses to hypoxia in tumor cells, and whether this will affect from mammary epithelial tissue (Hall et al., 1982) , as judged by tumorigenicity. growth in soft agar, growth to a higher saturation density, and Experimental procedures growth in low serum. Nor did KCNK9 overexpression in NIH-3T3 cells induce tumor formation following implanting the cells
Tumor samples and cell lines
into athymic mice. However, three out of five mice injected with Breast and lung human tumor samples were obtained from the Cooperative
KCNK9-overexpressing NMuMG cells formed tumors within 3
Human Tissue Network and Duke University. NMuMG cells were from ATCC. months, whereas none of the five mice that had been injected NIH-3T3, ZR-74-30, C8, and A9 cells were obtained from Cold Spring Harbor Laboratory. C8 and A9 are isogenic transformed cells that express both with control NMuMG cells formed tumors ( Figure 3A) . activated HRAS and E1A oncogenes; C8 cells contain wild-type TP53, while human genome sequence (http://www.ncbi.nlm.nih.gov/genome/seq/). The other four BACs (34D10, 381K12, 24E21, and 4P6-B) were sequenced at A9 cells contain a homozygous deletion of TP53 (Lanni et al., 1997) . Retroviral transfection was conducted as described (Serrano et al., 1997) . Genomic low-pass coverage (3ϫ to 6ϫ) without assembly, and their alignment in the contig shown in Figure 1 was performed by BLASTN analysis to the draft DNA was prepared using the proteinase K method, and total RNA was extracted using the Trizol reagent according to the manufacturer's protocol genome assembly of twenty 400 to 700 bp reads picked from each BAC at random in addition to the BAC end sequences. The DNA sequences of these (Invitrogen, Carlsbad, CA).
reads is available from the authors. One of these BACs, which we designated 4P6-B, is a subclone of the original stab received from Research Genetics Genomic methods and differs in its sequence from the GenBank sequence for 4P6 (AC007870). RDA and DNA hybridization using genomic representations was performed Exon trapping was performed with a kit from GIBCO-BRL (Invitrogen). as described (Lisitsyn et al., 1995; Lucito et al., 1998) . Radiation hybrid mapping of RDA probes was performed with the GeneBridge4 panel from Research Genetics (Invitrogen). The CITB human BAC library, release 4, was Quantitative PCR Fluorogenic Taqman Q-PCR probes were designed using the PrimerExpress purchased from Research Genetics (Invitrogen) and screened as recommended by the supplier with PCR primers to the RDA sequences. Both software (Applied Biosystems, Foster City, CA) and synthesized by Operon Technologies. DNA copy number was quantified using the ABI 7700 or ABI termini of positive BAC clones were sequenced and PCR primers were designed to allow identification of overlapping BAC clones from the same 7900 Sequence Detection Systems (Applied Biosystems, Foster City, CA). mRNA levels of KCNK9, KCNK3, and T1 in tumors and in corresponding library. Two of the six BACs (431C18 and 564L17 of accession AC007869 and AC007871, respectively) of the contig shown in Figure 1 were completely normal tissues (Clontech, Palo Alto, CA) were determined by performing quantitative PCR with fluorogenic TaqMan probes directly following reverse sequenced (Lander et al., 2001) , and their sequence is part of the current for three different samples of normal breast tissue and three different samples cDNA cloning KCNK9 was PCR amplified with Pfu Turbo polymerase (Stratagene) from ZR-75-30 cDNA using primers designed from the coding sequence predicted normalized to the highest of the three readings of KCNK9-C8 cells in 10% by GeneMachine analysis of the DNA sequence of BAC 431C18: 5Ј-TCATG serum. To subject cells to hypoxia, Modular Incubator Chambers were pur-GATCCACCATGAAGAGGCAGAACGTGCGGACTCTG and 5Ј-TTCCGAAT chased from Billups-Rothenberg (Del Mar, CA). 12-well culture plates bearing TCTAAACGGACTTCCGGCGTTTCATCAGC. Subsequently it was cloned 100,000 cells/well in triplicate were placed in the chambers and flushed with into BamHI/EcoRI sites of a retroviral vector, pLPC, and sequenced. Our low-oxygen air (0.02% oxygen, 5% carbon dioxide, 94.98% nitrogen) at KCNK9 cDNA sequence contains a silent single base transition (T→C) at 20-25 l/min for 5 min. The chambers were flushed with low-oxygen air twice the codon of amino acid Gly212 compared to our predicted KCNK9 cDNA daily and incubated at 37ЊC. After 3 days, viable cells were quantified using sequence. For cloning T1 cDNA, PCR primers to an exon trapping product Celltiter 96 Aqueous One Solution. Relative cell viability is expressed by of BAC 431C18 (5Ј-CGAGGTAGAAGGTGCTGGAG and 5Ј-ACGGACAGC normalizing all readings to highest of the three readings of KCNK9-A9 cells CATGTGACC) were used to screen arrayed human cDNA clones purchased exposed to normal air. Low-oxygen air tank was purchased from General from Origene (Rockville, MD) following the manufacturer's protocol. The
Welding (Westbury, NY). resulting cDNA clone was sequenced by constructing a series of nesteddeletion mutants. The GenBank accession number for the KCNK9 cDNA Other methods clone is AY190605 and for the T1 cDNA clone is AY190606.
Tissue microarray slides bearing normal breast and breast tumor sections were purchased from Imgenex (http://www.imgenex.com). Anti-TASK1 anti-Tumorigenicity, low-serum, and hypoxia assays bodies were purchased from Chemicon (http://www.chemicon.com). Polyclonal All functional assays were repeated at least twice with independently derived rabbit antibodies raised against KCNK9 peptide (REEEKLKAEEIRIKGKY retroviral transfectants. For tumorigenicity assays, 2 ϫ 10 5 of C8 cells and NISSEDYRQ) and secondary anti-rabbit antibodies purchased from Bio-5 ϫ 10 6 of NMuMG cells were injected s.c. into athymic mice (Crl:CD-1-nuBR genex (http://www.biogenex.com) were used to probe tissue slides following from Charles River, Wilmington, MA), with five mice for each transfectant per the manufacturer's protocol. individual experiment. Mice were observed weekly for tumor formation at the injection sites and tumor sizes were determined. For survival under low-
